1
|
Sonda K, Kodama T, Wea Siga MD, Masumoto K, Iwai M, Fadil M, Ahmad MS, Christopher Agutaya JK, Inomata Y, Quitain AT, Hardiansyah A, Kida T. Selective Detection of CO Using Proton-Conducting Graphene Oxide Membranes with Pt-Doped SnO 2 Electrocatalysts: Mechanistic Study by Operando DRIFTS. ACS Appl Mater Interfaces 2023. [PMID: 37917834 DOI: 10.1021/acsami.3c10349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2023]
Abstract
To reduce the risk of carbon monoxide (CO) poisoning, there is a strong need for small, compact gas sensors to detect and monitor CO at ppm concentrations. In this study, we focused on detecting CO with electrochemical sensors based on proton-conducting graphene oxide (GO) nanosheets at room temperature. We found that a Ce-doped GO nanosheet membrane fitted with the sensing electrode composed of Pt (10 wt %)-doped SnO2 nanocrystals exhibits an excellent sensor response to CO at 25 °C. Pt doping of SnO2 nanocrystals has made it possible to detect CO more selectively than H2 and ethanol. The CO detection mechanism is analyzed by operando diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS), Fourier transform infrared gas cell measurements, and comprehensive density functional theory-based calculations. The results revealed that adsorption of CO occurs predominantly on Pt sites, and the adsorbed CO is anodically oxidized at the interface between the sensing electrode and proton-conducting membrane, generating the selective sensor response. The strong adsorption of CO was realized with Pt (10 wt %)-doped SnO2 nanocrystals, as revealed by the DRIFTS analysis and temperature-programed desorption technique.
Collapse
Affiliation(s)
- Kosuke Sonda
- Department of Applied Chemistry and Biochemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Taiga Kodama
- Department of Applied Chemistry and Biochemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Maria Drira Wea Siga
- Department of Applied Chemistry and Biochemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Keigo Masumoto
- Department of Applied Chemistry and Biochemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Masaru Iwai
- Department of Applied Chemistry and Biochemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Muhammad Fadil
- Department of Applied Chemistry and Biochemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Muhammad Sohail Ahmad
- Institute of Industrial Nanomaterials (IINa), Kumamoto University, Kumamoto 860-8555, Japan
- International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Kumamoto 860-8555, Japan
| | - Jonas Karl Christopher Agutaya
- International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Kumamoto 860-8555, Japan
| | - Yusuke Inomata
- Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Armando T Quitain
- Center for International Education, Kumamoto University, Kumamoto 860-8555, Japan
| | - Andri Hardiansyah
- Research Center for Advanced Materials, National Research and Innovation Agency (BRIN), South Tangerang City, Banten 15314, Indonesia
| | - Tetsuya Kida
- Institute of Industrial Nanomaterials (IINa), Kumamoto University, Kumamoto 860-8555, Japan
- International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Kumamoto 860-8555, Japan
- Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| |
Collapse
|
2
|
Watanabe S, Hayashida T, Iwai M, Inomata Y, Kunitake M, Kida T. Single Crystallization of Cs 4PbBr 6 Perovskite from Supersaturated Organic Solutions Optimized Through Solubility Studies. ACS Omega 2023; 8:2455-2461. [PMID: 36687048 PMCID: PMC9850476 DOI: 10.1021/acsomega.2c06945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 12/21/2022] [Indexed: 06/17/2023]
Abstract
We demonstrate the fabrication of millimeter-sized single crystals of 0D-Cs4PbBr6 grown in a supersaturated solution consisting of organic solvents without HBr (aq). One of the precursors, CsBr, was dissolved in ethylene glycol (EG) mixed with dimethyl sulfoxide, which is a good solvent for the other precursor, PbBr2. At a solvent ratio of 20 vol % EG, the solubility of cesium bromide decreased and the title compound, Cs4PbBr6, was selectively formed, whereas, with an EG ratio of 80 vol %, 3D-CsPbBr3 was formed. A phase diagram (solubility curve) of Cs4PbBr6 in the mixed solvent containing 20 vol % EG was obtained by visually observing dissolution and crystal precipitation while changing the temperature. Because the solubility was proportional to the temperature, the solubility curve demonstrated an upper critical solution phenomenon. The solubility near the boiling point of the solution (150 °C) was approximately 0.14 M. A single crystal of Cs4PbBr6 was formed by growing a seed crystal in a supersaturated solution on the low-temperature side of the solubility curve. X-ray analysis established the crystal structure; a fluorescence emission at 520 nm with a full width at half maximum of 20 nm confirms the composition of the single crystal to be Cs4PbBr6.
Collapse
Affiliation(s)
- Satoshi Watanabe
- Faculty
of Advanced Science and Technology, Kumamoto
University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City, Kumamoto 860-8555, Japan
| | - Taiki Hayashida
- Faculty
of Advanced Science and Technology, Kumamoto
University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City, Kumamoto 860-8555, Japan
| | - Masaru Iwai
- Faculty
of Advanced Science and Technology, Kumamoto
University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City, Kumamoto 860-8555, Japan
| | - Yusuke Inomata
- Faculty
of Advanced Science and Technology, Kumamoto
University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City, Kumamoto 860-8555, Japan
| | - Masashi Kunitake
- Institute
of Industrial Nanomaterials, Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City, Kumamoto 860-8555, Japan
| | - Tetsuya Kida
- Institute
of Industrial Nanomaterials, Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City, Kumamoto 860-8555, Japan
| |
Collapse
|
3
|
Shinkai T, Masumoto K, Iwai M, Inomata Y, Kida T. Study on Sensing Mechanism of Volatile Organic Compounds Using Pt-Loaded ZnO Nanocrystals. Sensors (Basel) 2022; 22:6277. [PMID: 36016037 PMCID: PMC9415036 DOI: 10.3390/s22166277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 07/20/2022] [Accepted: 08/11/2022] [Indexed: 06/15/2023]
Abstract
Understanding the surface chemistry of target gases on sensing materials is essential for designing high-performance gas sensors. Here, we report the effect of Pt-loading on the sensing of volatile organic compounds (VOCs) with ZnO gas sensors, demonstrated by diffuse reflection infrared Fourier transform (DRIFT) spectroscopy. Pt-loaded ZnO nanocrystals (NCs) of 13~22 nm are synthesized using the hot soap method. The synthesized powder is deposited on an alumina substrate by screen-printing to form a particulate gas sensing film. The 0.1 wt% Pt-loaded ZnO NC sensor shows the highest sensor response to acetone and ethanol at 350 °C, while the responses to CO and H2 are small and exhibit good selectivity to VOCs. The gas sensing mechanism of ethanol with Pt-ZnO NCs was studied by in situ DRIFT spectroscopy combined with online FT-IR gas analysis. The results show that ethanol reacts with small Pt-loaded ZnO to produce intermediate species such as acetaldehyde, acetate, and carbonate, which generates a high sensor response to ethanol in air.
Collapse
Affiliation(s)
- Takeshi Shinkai
- Department of Material Science and Applied Chemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Keigo Masumoto
- Department of Material Science and Applied Chemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Masaru Iwai
- Department of Material Science and Applied Chemistry, Graduate School of Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Yusuke Inomata
- Division of Materials Science, Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
| | - Tetsuya Kida
- Division of Materials Science, Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan
- Institute of Industrial Nanomaterials, Kumamoto University, Kumamoto 860-8555, Japan
- International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University, Kumamoto 860-8555, Japan
| |
Collapse
|
4
|
Niki A, Ochiai D, Iwai M, Sato Y, Yoshino K, Yamada T. Management of pregnancy complicated by central core disease. Int J Obstet Anesth 2020; 43:25-26. [PMID: 32570046 DOI: 10.1016/j.ijoa.2020.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 05/17/2020] [Accepted: 05/19/2020] [Indexed: 11/29/2022]
Affiliation(s)
- A Niki
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - D Ochiai
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
| | - M Iwai
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - Y Sato
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
| | - K Yoshino
- Department of Anesthesiology, Keio University School of Medicine, Tokyo, Japan
| | - T Yamada
- Department of Anesthesiology, Keio University School of Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Grosicki GJ, Englund DA, Price L, Iwai M, Kashiwa M, Reid KF, Fielding RA. Lower-Extremity Torque Capacity and Physical Function in Mobility-Limited Older Adults. J Nutr Health Aging 2019; 23:703-709. [PMID: 31560027 PMCID: PMC7386562 DOI: 10.1007/s12603-019-1232-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVES Skeletal muscle weakness and an increase in fatigability independently contribute to age-related functional decline. The objective of this study was to examine the combined contribution of these deficiencies (i.e., torque capacity) to physical function, and then to assess the functional implications of progressive resistance training (PRT) mediated-torque capacity improvements in mobility-limited older adults. DESIGN Randomized controlled trial. SETTING Exercise laboratory on the Health Sciences campus of an urban university. PARTICIPANTS Seventy mobility-limited (Short Physical Performance Battery (SPPB) ≤9) older adults (~79 yrs). INTERVENTION Progressive resistance training or home-based flexibility 3 days/week for 12 weeks. MEASUREMENTS Torque capacity was defined as the sum of peak torques from an isokinetic knee extension fatigue test. Relationships between torque capacity and performance-based and patient-reported functional measures before and after PRT were examined using partial correlations adjusted for age, sex, and body mass index. RESULTS Torque capacity explained (P<0.05) 10 and 28% of the variance in six-minute walk distance and stair climb time, respectively. PRT-mediated torque capacity improvements were paralleled by increases (P<0.05) in self-reported activity participation (+20%) and advanced lower extremity function (+7%), and associated (P<0.05) with a reduction in activity limitations (r=0.44) and an improved SPPB score (r=0.32). CONCLUSION Skeletal muscle torque capacity, a composite of strength and fatigue, may be a proximal determinant of physical function in mobility-limited older individuals. To more closely replicate the musculoskeletal demands of real-life tasks, future studies are encouraged to consider the combined interaction of distinct skeletal muscle faculties to overall functional ability in older adults.
Collapse
Affiliation(s)
- G J Grosicki
- Gregory J. Grosicki, Ph.D., Department of Health Sciences and Kinesiology, Biodynamics and Human Performance Center, Georgia Southern University (Armstrong Campus), 11935 Abercorn Street, Savannah, GA, 31419. Phone: (912) 344-3317. Fax: (912) 344-3490.
| | | | | | | | | | | | | |
Collapse
|
6
|
Grosicki G, Englund D, Price L, Iwai M, Kashiwa M, Liu C, Reid K, Fielding R. SKELETAL MUSCLE FATIGABILITY PREDICTS PHYSICAL FUNCTION IN MOBILITY-LIMITED OLDER ADULTS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- G Grosicki
- Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
| | - D Englund
- Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
| | - L Price
- The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Boston, MA, USA
| | - M Iwai
- Astellas Pharma Inc., Itabashi ku, Tokyo, Japan
| | - M Kashiwa
- Astellas Pharma Inc., Itabashi ku, Tokyo, Japan
| | - C Liu
- Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University; Geriatrics Section, Department of Medicine, Boston Medical Center, Boston, MA, USA
| | - K Reid
- Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
| | - R Fielding
- Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
| |
Collapse
|
7
|
Kimura M, Iwai M, Usami E, Teramachi H, Yoshimura T. Prognostic factors in patients with advanced and recurrent colorectal cancer receiving last-line chemotherapy. Pharmazie 2018; 73:115-119. [PMID: 29442015 DOI: 10.1691/ph.2018.7832] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
For patients with advanced/recurrent colorectal cancer, the trifluridine/tipiracil combination tablet (TAS 102) and regorafenib are last-line treatments. This study aimed to clarify prognostic factors in patients receiving last-line chemotherapy. Between April 2014 and December 2016, 47 patients received last-line chemotherapy at Ogaki Municipal Hospital, Japan. The primary outcome was overall survival. To determine factors associated with survival, those considered significant in the univariate analysis (p <0.10), were entered into a multivariate Cox proportional hazards model. KRAS type and the use of opioid formulations were independently and significantly associated with survival in the multivariate analysis. For patients with KRAS-wild relative to KRAS-mutation cancers, the hazard ratio for death was 0.478 (95% CI, 0.249-0.919; p = 0.03). For patients taking opioid formulations, relative to those not, the hazard ratio for death was 3.557 (95% CI, 1.032-12.257; p = 0.04). The median overall survival duration for patients with KRAS-wild (n = 24) and KRAS-mutation (n = 23) cancers were 223.5 days (range: 115-703) and 154 days (range: 51-503), respectively (p = 0.05). This finding provides a useful index to make an early decision on discontinuation of treatment and to guide decisions around agents to use in last-line chemotherapy.
Collapse
|
8
|
Kimura M, Yasue F, Usami E, Kawachi S, Iwai M, Go M, Ikeda Y, Yoshimura T. Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Mol Clin Oncol 2018; 9:201-206. [PMID: 30101022 DOI: 10.3892/mco.2018.1640] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Accepted: 05/29/2018] [Indexed: 02/07/2023] Open
Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non-small cell lung cancer. The present study aimed to compare the cost-effectiveness of using erlotinib, afatinib or gefitinib. The safety of EGFR-TKIs was also investigated. Expected costs were calculated based on data from patients with advanced EGFR mutation-positive non-small-cell lung cancer who were treated with gefitinib, erlotinib or afatinib. Literature was collected to obtain the necessary clinical information for calculating the probability and the validity of each chemotherapy. Median survival time (MST) was used to evaluate the therapeutic effect of the regimens. The cost-effectiveness ratio was calculated using expected costs and MSTs for the three regimens. The cost-effectiveness ratio per month was JPY 386,859.4/MST for afatinib, JPY 264,788.7/MST for gefitinib and JPY 397,039.9/MST for erlotinib. Significant differences were observed between the three groups (p<0.001). The incremental cost-effectiveness ratio (ICER) of gefitinib compared with afatinib per month was JPY 122,070.7/MST. The ICER of gefitinib compared with erlotinib was JPY -69,605.9/MST. Adverse effects of Grade 3 and higher, including diarrhoea (28.6%) and paronychia (14.3%) were observed in the afatinib treatment group. Paronychia (23.1%) was observed in the erlotinib treatment group, while none were observed in the gefitinib treatment group. These findings demonstrate that gefitinib is more cost effective in comparison with the afatinib and erlotinib regimens, although the afatinib and erlotinib regimens were well-tolerated and produce sufficient effects.
Collapse
Affiliation(s)
- M Kimura
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan
| | - F Yasue
- Faculty of Pharmaceutical Sciences, Kinjo Gakuin University, Nagoya-shi, Aichi 463-8521, Japan
| | - E Usami
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan
| | - S Kawachi
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan
| | - M Iwai
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan
| | - M Go
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan
| | - Y Ikeda
- Faculty of Pharmaceutical Sciences, Kinjo Gakuin University, Nagoya-shi, Aichi 463-8521, Japan
| | - T Yoshimura
- Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan
| |
Collapse
|
9
|
Iwai M, Ito D, Asano H, Adachi S, Okada K, Kimura M, Usami E, Matsuo K, Yoshimura T, Teramachi H. Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer. Pharmazie 2018; 73:309-312. [PMID: 29724300 DOI: 10.1691/ph.2018.7355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
As a result of the RAINBOW trial, ramucirumab plus paclitaxel was established as a second-line treatment of advanced gastric cancer. Regarding the safety of ramucirumab plus paclitaxel in the Japanese, a subgroup analysis of the RAINBOW trial was conducted. The incidence of neutropenia was higher in Japanese patients. However, information is lacking concerning the safety of ramucirumab after marketing in Japanese patients. Therefore, the aim of this study was to evaluate the safety of ramucirumab in Japanese patients with advanced gastric cancer. The inclusion criteria were patients diagnosed with advanced gastric cancer who had commenced treatment with ramucirumab plus paclitaxel or paclitaxel only at Ogaki Municipal Hospital (Gifu, Japan) between January 2015 and December 2016. There were 26 patients in the ramucirumab plus paclitaxel group and 22 patients in the paclitaxel only group. Treatment-related adverse events were documented in 100.0% of the patients in the ramucirumab plus paclitaxel group (Grade 3-4, 73.1%) and 90.9 % of the patients in the paclitaxel only group (Grade 3-4, 45.5 %). The most frequently observed adverse event in both treatment groups was anemia. The second common adverse event was neutropenia. The incidence of neutropenia of Grade ≥3 was significantly higher in the ramucirumab plus paclitaxel group than in the paclitaxel only group. In conclusion, the incidence of neutropenia is high. However, we believe that ramucirumab plus paclitaxel can be safely administered.
Collapse
|
10
|
Yasue F, Kimura M, Usami E, Iwai M, Kawachi S, Mitsuoka M, Ikeda Y, Yoshimura T. Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer. Pharmazie 2018; 73:178-181. [PMID: 29544568 DOI: 10.1691/ph.2018.7908] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Elucidating the factors influencing severe neutropenia could aid in earlier management of neutropenia during oral trifluridine-tipiracil (TAS-102) chemotherapy in advanced and recurrent colorectal cancer (CRC). This study was conducted to assess the risk of TAS-102-induced grade 3 or more neutropenia. Between August 2014 and July 2017, 60 patients underwent oral TAS-102 monotherapy at Ogaki Municipal Hospital, Japan. The patients were divided into two groups based on the development of grade 3 or more neutropenia (9 patients) or not (51 patients). Risk factors for grade 3 or more neutropenia were examined by univariate and multivariate analyses. Creatinine clearance rate (CrCl) before TAS-102 administration significantly correlated with the incidence of Grade 3 or more neutropenia after TAS-102 administration (odds ratio 6.5, 95% confidence interval 1.14-30.00; p = 0.02). Multivariate analysis revealed that a CrCl of lower than 57.1 mL/min before TAS-102 administration (odds ratio 54.06, 95% confidence interval 2.14-1364.2; p = 0.02) was an independent risk factor significantly contributing to the development of grade 3 or more neutropenia, induced by TAS-102. CrCl < 57.1 mL/min in patients with advanced and recurrent CRC who underwent TAS-102 chemotherapy was associated with grade 3 or more neutropenia.
Collapse
|
11
|
Motomura H, Watanabe J, Togo S, Sumiyoshi I, Namba Y, Suina K, Mizuno T, Kadoya K, Iwai M, Nagaoka T, Sasaki S, Hayashi T, Uekusa T, Abe K, Urata Y, Sakurai F, Mizuguchi H, Kato S, Takahashi K. P1.03-006 Clinicopathological Features and Poor Outcome for ALK Inhibitors of Squamous Cell Lung Cancer with ALK-Rearrangement. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Leonhardt J, Villela DC, Teichmann A, Münter LM, Mayer MC, Mardahl M, Kirsch S, Namsolleck P, Lucht K, Benz V, Alenina N, Daniell N, Horiuchi M, Iwai M, Multhaup G, Schülein R, Bader M, Santos RA, Unger T, Steckelings UM. Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS. Hypertension 2017; 69:1128-1135. [PMID: 28461604 DOI: 10.1161/hypertensionaha.116.08814] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 12/21/2016] [Accepted: 04/06/2017] [Indexed: 11/16/2022]
Abstract
The angiotensin type 2 receptor (AT2R) and the receptor MAS are receptors of the protective arm of the renin-angiotensin system. They mediate strikingly similar actions. Moreover, in various studies, AT2R antagonists blocked the effects of MAS agonists and vice versa. Such cross-inhibition may indicate heterodimerization of these receptors. Therefore, this study investigated the molecular and functional interplay between MAS and the AT2R. Molecular interactions were assessed by fluorescence resonance energy transfer and by cross correlation spectroscopy in human embryonic kidney-293 cells transfected with vectors encoding fluorophore-tagged MAS or AT2R. Functional interaction of AT2R and MAS was studied in astrocytes with CX3C chemokine receptor-1 messenger RNA expression as readout. Coexpression of fluorophore-tagged AT2R and MAS resulted in a fluorescence resonance energy transfer efficiency of 10.8 ± 0.8%, indicating that AT2R and MAS are capable to form heterodimers. Heterodimerization was verified by competition experiments using untagged AT2R and MAS. Specificity of dimerization of AT2R and MAS was supported by lack of dimerization with the transient receptor potential cation channel, subfamily C-member 6. Dimerization of the AT2R was abolished when it was mutated at cysteine residue 35. AT2R and MAS stimulation with the respective agonists, Compound 21 or angiotensin-(1-7), significantly induced CX3C chemokine receptor-1 messenger RNA expression. Effects of each agonist were blocked by an AT2R antagonist (PD123319) and also by a MAS antagonist (A-779). Knockout of a single of these receptors made astrocytes unresponsive for both agonists. Our results suggest that MAS and the AT2R form heterodimers and that-at least in astrocytes-both receptors functionally depend on each other.
Collapse
Affiliation(s)
- Julia Leonhardt
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Daniel C Villela
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Anke Teichmann
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Lisa-Marie Münter
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Magnus C Mayer
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Maibritt Mardahl
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Sebastian Kirsch
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Pawel Namsolleck
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Kristin Lucht
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Verena Benz
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Natalia Alenina
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Nicholas Daniell
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Masatsugu Horiuchi
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Masaru Iwai
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Gerhard Multhaup
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Ralf Schülein
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Michael Bader
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Robson A Santos
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Thomas Unger
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.)
| | - Ulrike Muscha Steckelings
- From the Center for Cardiovascular Research, Charité-Medical Faculty Berlin, Germany (J.L., D.C.V., M.M., S.K., P.N., K.L., V.B., N.D., T.U., U.M.S.); The Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) and Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Germany (J.L.); Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil (D.C.V., R.A.S.); Faculty of Medicine, Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, Brazil (D.C.V.); Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany (A.T., R.S.); Institut für Chemie und Biochemie, Free University Berlin, Germany (L.-M.M., M.C.M., G.M.); Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada (L.-M.M., G.M.); CARIM, Maastricht University, The Netherlands (P.N., T.U.); Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany (N.A., M.B.); Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Japan (M.H., M.I.); and IMM-Department of Cardiovascular and Renal Research, University of Southern Denmark, Odense (U.M.S.).
| |
Collapse
|
13
|
Iwai M, Kobayashi K. Dimensional contraction by principal component analysis as preprocessing for independent component analysis at MCG. Biomed Eng Lett 2017; 7:221-227. [PMID: 30603169 DOI: 10.1007/s13534-017-0024-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Revised: 03/20/2017] [Accepted: 03/23/2017] [Indexed: 10/19/2022] Open
Abstract
We propose a noise reduction method for magnetocardiograms (MCGs) based on independent component analysis (ICA). ICA is useful to separate the noise and signal components, but ICA-based automatic noise reduction faces two main difficulties: the dimensional contraction process applied after the principal component analysis (PCA) used for preprocessing, and the component selection applied after ICA. The results of noise reduction vary among people, because these two processes typically depend on personal qualitative evaluations of the obtained components. Therefore, automatic quantitative ICA-based noise reduction is highly desirable. We will focus on the first difficulty, by improving the index used in the dimensional contraction process. The index used for component ordering after PCA affects the accuracy of separation obtained with ICA. The contribution ratio is often used as an index. However, its efficacy is highly dependent on the signal-to-noise ratio (SNR) it unsuitable for automation. We propose a kurtosis-based index, whose efficacy does not depend on SNR. We compare the two decision indexes through simulation. First, we evaluate their preservation rate of the MCG information after dimensional contraction. In addition, we evaluate their effect on the accuracy of the ICA-based noise reduction method. The obtained results show that the kurtosis-based index does preserve the MCG signal information through dimensional contraction, and has a more consistent behavior when the number of components increases. The proposed index performs better than the traditional index, especially in low SNRs. As such, it paves the way for the desired noise reduction process automation.
Collapse
Affiliation(s)
- M Iwai
- Iwate University, 4-3-5 Ueda, Morioka, Iwate 020-8551 Japan
| | - K Kobayashi
- Iwate University, 4-3-5 Ueda, Morioka, Iwate 020-8551 Japan
| |
Collapse
|
14
|
Liu Z, Yanagisawa K, Griesing S, Iwai M, Kano K, Hotta N, Kajino T, Suzuki M, Takahashi T. TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas. Oncogene 2017; 36:3740-3748. [PMID: 28192407 DOI: 10.1038/onc.2016.524] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2016] [Revised: 12/17/2016] [Accepted: 12/21/2016] [Indexed: 01/19/2023]
Abstract
TTF-1, also known as NKX2-1, is a transcription factor that has indispensable roles in both lung development and physiology. We and others have reported that TTF-1 frequently exhibits high expression with increased copy number in lung adenocarcinomas, and also has a role as a lineage-survival oncogene through transcriptional activation of crucial target genes including ROR1 and LMO3. In the present study, we employed a global proteomic search for proteins that interact with TTF-1 in order to provide a more comprehensive picture of this still enigmatic lineage-survival oncogene. Our results unexpectedly revealed a function independent of its transcriptional activity, as TTF-1 was found to interact with DDB1 and block its binding to CHK1, which in turn attenuated ubiquitylation and subsequent degradation of CHK1. Furthermore, TTF-1 overexpression conferred resistance to cellular conditions under DNA replication stress (RS) and prevented an increase in consequential DNA double-strand breaks, as reflected by attenuated induction of pCHK2 and γH2AX. Our findings suggest that the novel non-transcriptional function of TTF-1 identified in this study may contribute to lung adenocarcinoma development by conferring tolerance to DNA RS, which is known to be inherently elicited by activation of various oncogenes.
Collapse
Affiliation(s)
- Z Liu
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Yanagisawa
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Griesing
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Iwai
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - K Kano
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - N Hotta
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Kajino
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Suzuki
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - T Takahashi
- Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
15
|
Kimura M, Usami E, Iwai M, Teramachi H, Yoshimura T. Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy. Pharmazie 2017; 72:49-52. [PMID: 29441897 DOI: 10.1691/ph.2017.6808] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
BACKGROUND/AIM The effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated. PATIENTS AND METHODS Between August 2014 and May 2016, 41 patients underwent TAS-102 monotherapy at Ogaki Municipal Hospital. Risk factors for survival were examined by univariate and multivariate analyses. RESULTS In 41 patients, mild neutropenia (grade 1-2) occurred in 10 patients (24.4%), severe neutropenia (grade 3-4) occurred in 13 (31.7%), and 18 (43.9%) did not experience neutropenia. The median overall survival times in the absent, mild, and severe groups were 120 days (95% confidence interval [CI], 67-179), 184 days (95% CI, 94-274), and 299 days (95% CI, 192-404), respectively (p = 0.045). In patients with severe neutropenia, the death hazard ratio was 0.442 (95% CI, 0.201-0.974; p = 0.042). CONCLUSION In patients with advanced/recurrent colorectal cancer, TAS-102-induced severe neutropenia was associated with superior survival.
Collapse
|
16
|
Uto S, Kawakami K, Umena Y, Iwai M, Ikeuchi M, Shen JR, Kamiya N. Mutual relationships between structural and functional changes in a PsbM-deletion mutant of photosystem II. Faraday Discuss 2017; 198:107-120. [DOI: 10.1039/c6fd00213g] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Photosystem II (PSII) is a membrane protein complex that performs light-induced electron transfer and oxygen evolution from water. PSII consists of 19 or 20 subunits in its crystal form and binds various cofactors such as chlorophyll a, plastoquinone, carotenoid, and lipids. After initial light excitation, the charge separation produces an electron, which is transferred to a plastoquinone molecule (QA) and then to another plastoquinone (QB). PsbM is a low-molecular-weight subunit with one transmembrane helix, and is located in the monomer–monomer interface of the PSII dimer. The function of PsbM has been reported to be stabilization of the PSII dimer and maintenance of electron transfer efficiency of PSII based on previous X-ray crystal structure analysis at a resolution of 4.2 Å. In order to elucidate the structure–function relationships of PsbM in detail, we improved the quality of PSII crystals from a PsbM-deleted mutant (ΔPsbM-PSII) of Thermosynechococcus elongatus, and succeeded in improving the diffraction quality to a resolution of 2.2 Å. X-ray crystal structure analysis of ΔPsbM-PSII showed that electron densities for the PsbM subunit and neighboring carotenoid and detergent molecules were absent in the monomer–monomer interface. The overall structure of ΔPsbM-PSII was similar to wild-type PSII, but the arrangement of the hydrophobic transmembrane subunits was significantly changed by the deletion of PsbM, resulting in a slight widening of the lipid hole involving QB. The lipid hole-widening further induced structural changes of the bicarbonate ion coordinated to the non-heme Fe(ii) atom and destabilized the polypeptide chains around the QB binding site located far from the position of PsbM. The fluorescence decay measurement indicated that the electron transfer rate from QA to QB was decreased in ΔPsbM-PSII compared with wild-type PSII. The functional change in electron transfer efficiency was fully interpreted based on structural changes caused by the deletion of the PsbM subunit.
Collapse
Affiliation(s)
- S. Uto
- Department of Chemistry
- Graduate School of Science
- Osaka City University
- Osaka
- Japan
| | - K. Kawakami
- The OCU Advanced Research Institute for Natural Science and Technology (OCARINA)
- Osaka City University
- Osaka
- Japan
| | - Y. Umena
- The OCU Advanced Research Institute for Natural Science and Technology (OCARINA)
- Osaka City University
- Osaka
- Japan
- JST-PRESTO
| | - M. Iwai
- Graduate School of Bioscience and Biotechnology
- Tokyo Institute of Technology
- Yokohama
- Japan
| | - M. Ikeuchi
- Department of Life Sciences (Biology)
- Graduate School of Arts and Science
- The University of Tokyo
- Tokyo
- Japan
| | - J.-R. Shen
- Research Institute for Interdisciplinary Science
- Okayama University
- Okayama
- Japan
| | - N. Kamiya
- Department of Chemistry
- Graduate School of Science
- Osaka City University
- Osaka
- Japan
| |
Collapse
|
17
|
Mizuno Y, Fuchikami H, Takeda N, Iwai M, Sato K. Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy. Jpn J Clin Oncol 2016; 47:12-17. [PMID: 28122890 DOI: 10.1093/jjco/hyw152] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 09/18/2016] [Accepted: 09/19/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This retrospective study aimed to evaluate the efficacy of a 3.6-mg dose of pegfilgrastim for primary prophylaxis in Japanese breast cancer patients receiving dose-dense chemotherapy. METHODS Patients treated with adjuvant or neoadjuvant chemotherapy for early-stage breast cancer at the Tokyo-West Tokushukai Hospital were included in this analysis. Because 6 mg pegfilgrastim has not yet been approved for use in Japan, we compared the outcomes of a dose-dense doxorubicin and cyclophosphamide regimen plus 3.6 mg pegfilgrastim support with a conventional dose epirubicin and cyclophosphamide regimen. The incidence of febrile neutropenia, relative dose intensity, dose delay, dose reduction, regimen change and hospitalization because of neutropenia were assessed. RESULTS From November 2013 to March 2016, 97 patients with stage I-III invasive breast cancer were analyzed (dose-dense doxorubicin and cyclophosphamide plus 3.6-mg pegfilgrastim group, n = 41; epirubicin and cyclophosphamide group, n = 56; median ages, 49.0 and 48.5 years, respectively). Febrile neutropenia occurred during the first chemotherapy cycle in 7 of 56 patients (12.5%) in the epirubicin and cyclophosphamide group and 0 of 41 patients in the dose-dense doxorubicin and cyclophosphamide group (P = 0.02). The average relative dose intensities were 97.9% and 96.8%, respectively (P = 0.28), with corresponding dose delay rates of 4.9% (2/41) and 16.1% (9/56), respectively (P = 0.11) and dose reduction rates of 0% (0/41) and 7.1% (4/56), respectively (P = 0.16). CONCLUSIONS Our results indicate the efficacy of a 3.6-mg pegfilgrastim dose for the primary prevention of febrile neutropenia in dose-dense doxorubicin- and cyclophosphamide-treated Japanese breast cancer patients.
Collapse
Affiliation(s)
- Yoshio Mizuno
- Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003
| | - Hiromi Fuchikami
- Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003
| | - Naoko Takeda
- Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003
- Inoue Ladies Clinic, Tachikawa, Tokyo 190-0013, Japan
| | - Masaru Iwai
- Department of Pharmacy, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003
| | - Kazuhiko Sato
- Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003
| |
Collapse
|
18
|
Kimura M, Go M, Iwai M, Ito D, Asano H, Usami E, Teramachi H, Yoshimura T. Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. Pharmazie 2016; 71:218-221. [PMID: 27209703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
We retrospectively studied the safety of trifluridine/tipiracil combination tablet (TAS-102) monotherapy in patients with advanced and recurrent colorectal cancer. Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95.7%). The most frequent adverse events were neutropenia (69.6%), nausea (53.2%), and malaise (30.4%). Treatment was postponed in 54 (59.3%) out of 91 courses, and in 34 (66.7%) of these 54 courses, the delay in treatment was due to bone marrow suppression. Seven patients with peritoneal metastases suffered from nausea, whilst none of the patients without peritoneal metastases had nausea (p = 0.0139). Nausea and vomiting during a previous chemotherapy cycle was significantly associated with nausea after TAS-102 treatment (p = 0.0007), and the treatment cycles were significantly longer in patients with grade 3 or 4 neutropenia (p = 0.0061). Our results suggest that the incidence of nausea was higher in patients treated with TAS-102. Therefore, it is important to inform patients of the risk of these toxicities and to provide enhanced supportive care. Moreover, we recommend that, for patients with repeated treatment postponement due to neutropenia, the dosage should be fixed based on therapeutic efficacy and prognosis.
Collapse
|
19
|
Schwengel K, Namsolleck P, Lucht K, Clausen BH, Lambertsen KL, Valero-Esquitino V, Thöne-Reineke C, Müller S, Widdop RE, Denton KM, Horiuchi M, Iwai M, Boato F, Dahlöf B, Hallberg A, Unger T, Steckelings UM. Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice. J Mol Med (Berl) 2016; 94:957-66. [PMID: 26983606 DOI: 10.1007/s00109-016-1406-3] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Revised: 01/30/2016] [Accepted: 02/18/2016] [Indexed: 01/09/2023]
Abstract
This study investigated the effect of post-stroke, direct AT2-receptor (AT2R) stimulation with the non-peptide AT2R-agonist compound 21 (C21) on infarct size, survival and neurological outcome after middle cerebral artery occlusion (MCAO) in mice and looked for potential underlying mechanisms. C57/BL6J or AT2R-knockout mice (AT2-KO) underwent MCAO for 30 min followed by reperfusion. Starting 45 min after MCAO, mice were treated once daily for 4 days with either vehicle or C21 (0.03 mg/kg ip). Neurological deficits were scored daily. Infarct volumes were measured 96 h post-stroke by MRI. C21 significantly improved survival after MCAO when compared to vehicle-treated mice. C21 treatment had no impact on infarct size, but significantly attenuated neurological deficits. Expression of brain-derived neurotrophic factor (BDNF), tyrosine kinase receptor B (TrkB) (receptor for BDNF) and growth-associated protein 43 (GAP-43) were significantly increased in the peri-infarct cortex of C21-treated mice when compared to vehicle-treated mice. Furthermore, the number of apoptotic neurons was significantly decreased in the peri-infarct cortex in mice treated with C21 compared to controls. There were no effects of C21 on neurological outcome, infarct size and expression of BDNF or GAP-43 in AT2-KO mice. From these data, it can be concluded that AT2R stimulation attenuates early mortality and neurological deficits after experimental stroke through neuroprotective mechanisms in an AT2R-specific way. Key message • AT2R stimulation after MCAO in mice reduces mortality and neurological deficits.• AT2R stimulation increases BDNF synthesis and protects neurons from apoptosis.• The AT2R-agonist C21 acts protectively when applied post-stroke and peripherally.
Collapse
Affiliation(s)
- Katja Schwengel
- Center for Cardiovascular Research, Medical Faculty, Charité, Berlin, Germany
| | | | - Kristin Lucht
- Center for Cardiovascular Research, Medical Faculty, Charité, Berlin, Germany
| | - Bettina H Clausen
- Department of Neurobiology, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | - Kate L Lambertsen
- Department of Neurobiology, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark
| | | | | | - Susanne Müller
- Experimental Neurology, Medical Faculty, Charité, Berlin, Germany
| | - Robert E Widdop
- Department of Pharmacology, Monash University, Clayton, Australia
| | - Kate M Denton
- Department of Physiology, Monash University, Clayton, Australia
| | - Masatsugu Horiuchi
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Ehime, Japan
| | - Masaru Iwai
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Ehime, Japan
| | - Francesco Boato
- Burke Medical Research Institute, Weill Cornell Medical College, Cornell University, White Plains, USA
| | - Björn Dahlöf
- Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Anders Hallberg
- Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
| | - Thomas Unger
- CARIM, Maastricht University, Maastricht, The Netherlands
| | - U Muscha Steckelings
- Department of Cardiovascular and Renal Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark.
| |
Collapse
|
20
|
Fares-Taie L, Gerber S, Tawara A, Ramirez-Miranda A, Douet JY, Verdin H, Guilloux A, Zenteno J, Kondo H, Moisset H, Passet B, Yamamoto K, Iwai M, Tanaka T, Nakamura Y, Kimura W, Bole-Feysot C, Vilotte M, Odent S, Vilotte JL, Munnich A, Regnier A, Chassaing N, De Baere E, Raymond-Letron I, Kaplan J, Calvas P, Roche O, Rozet JM. Submicroscopic deletions at 13q32.1 cause congenital microcoria. Am J Hum Genet 2015; 96:631-9. [PMID: 25772937 DOI: 10.1016/j.ajhg.2015.01.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2014] [Accepted: 01/20/2015] [Indexed: 11/25/2022] Open
Abstract
Congenital microcoria (MCOR) is a rare autosomal-dominant disorder characterized by inability of the iris to dilate owing to absence of dilator pupillae muscle. So far, a dozen MCOR-affected families have been reported worldwide. By using whole-genome oligonucleotide array CGH, we have identified deletions at 13q32.1 segregating with MCOR in six families originating from France, Japan, and Mexico. Breakpoint sequence analyses showed nonrecurrent deletions in 5/6 families. The deletions varied from 35 kbp to 80 kbp in size, but invariably encompassed or interrupted only two genes: TGDS encoding the TDP-glucose 4,6-dehydratase and GPR180 encoding the G protein-coupled receptor 180, also known as intimal thickness-related receptor (ITR). Unlike TGDS which has no known function in muscle cells, GPR180 is involved in the regulation of smooth muscle cell growth. The identification of a null GPR180 mutation segregating over two generations with iridocorneal angle dysgenesis, which can be regarded as a MCOR endophenotype, is consistent with the view that deletions of this gene, with or without the loss of elements regulating the expression of neighboring genes, are the cause of MCOR.
Collapse
|
21
|
Iwai M, Fuchikami H, Mizuno Y, Takeda N, Inoue Y, Seto H, Kudo T, Sato K. [Factors affecting adherence of breast cancer patients to adjuvant hormonal therapy and validation of the evaluation method]. Gan To Kagaku Ryoho 2014; 41:843-847. [PMID: 25131869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND The long-term use of hormonal therapy is important for the treatment of patients with breast cancer. Therefore, we evaluated the methods used for measuring adherence and examined factors that influence compliance. Our goal was to improve overall adherence to the treatment. METHODS Retrospective analyses by using electronic medical records and questionnaires were performed on 294 patients with breast cancer. The patients were classified into 2 groups based on the mean number of days when a dose was missed over a period of 28 days: group A(range, 0-3 days, n=272)and group B (range, B4 days, n=22). Factors that may influence adherence, including age, duration of hormonal therapy, the drug administered in hormonal therapy, the surgical method, axillary lymph node dissection, and adjuvant chemotherapy, were compared between both groups. RESULTS The adherence rates calculated from electronic medical records and questionnaires were similar. The proportion of patients younger than 50 years was 30% in group A and 50% in group B(p<0.05). Additionally, there was a difference in the duration of hormone therapy(752 days vs 981 days in groups A and B, respectively; p< 0.05). Additional factors that are related to low-risk cancer-related procedures, such as breast conserving surgery, may also be linked to poor adherence. CONCLUSION Young age and long duration of hormonal therapy are possibly related to poor adherence. Therefore, pharmacists should identify and manage these patients to increase adherence.
Collapse
Affiliation(s)
- Masaru Iwai
- Dept. of Pharmacy,Tokyo-West Tokushukai Hospital
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Kagotani A, Ishida M, Yoshida K, Iwai M, Okabe H. High-grade urothelial carcinoma of the bladder with rhabdoid features: cytological and histological report of two cases. Cytopathology 2014; 26:54-6. [DOI: 10.1111/cyt.12139] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- A. Kagotani
- Division of Diagnostic Pathology; Department of Clinical Laboratory Medicine; Shiga University of Medical Science; Shiga Japan
| | - M. Ishida
- Division of Diagnostic Pathology; Department of Clinical Laboratory Medicine; Shiga University of Medical Science; Shiga Japan
| | - K. Yoshida
- Division of Diagnostic Pathology; Department of Clinical Laboratory Medicine; Shiga University of Medical Science; Shiga Japan
| | - M. Iwai
- Division of Diagnostic Pathology; Department of Clinical Laboratory Medicine; Shiga University of Medical Science; Shiga Japan
| | - H. Okabe
- Division of Diagnostic Pathology; Department of Clinical Laboratory Medicine; Shiga University of Medical Science; Shiga Japan
| |
Collapse
|
23
|
Hashimoto T, Ajimura S, Beer G, Bhang H, Bragadireanu M, Buehler P, Busso L, Cargnelli M, Choi S, Curceanu C, Enomoto S, Faso D, Fujioka H, Fujiwara Y, Fukuda T, Guaraldo C, Hayano RS, Hiraiwa T, Iio M, Iliescu M, Inoue K, Ishiguro Y, Ishikawa T, Ishimoto S, Ishiwatari T, Itahashi K, Iwai M, Iwasaki M, Kato Y, Kawasaki S, Kienle P, Kou H, Ma Y, Marton J, Matsuda Y, Mizoi Y, Morra O, Nagae T, Noumi H, Ohnishi H, Okada S, Outa H, Piscicchia K, Poli Lener M, Romero Vida A, Sada Y, Sakaguchi A, Sakuma F, Sato M, Scordo A, Sekimoto M, Shi H, Sirghi D, Sirghi F, Suzuki K, Suzuki S, Suzuki T, Tanida K, Tatsuno H, Tokuda M, Tomono D, Toyoda A, Tsukada K, Vazquez Doce O, Widmann E, Wuenschek BK, Yamaga T, Yamazaki T, Yim H, Zhang Q, Zmeska J. A search for the K−ppbound state in the 3He( K−in-flight, n) reaction at J-PARC. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20146609008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Sada Y, Ajimura S, Beer G, Bhang H, Bragadireanu M, Buehler P, Busso L, Cargnelli M, Choi S, Curceanu C, Enomoto S, Faso D, Fujioka H, Fujiwara Y, Fukuda T, Guaraldo C, Hashimoto T, Hayano RS, Hiraiwa T, Iio M, Iliescu M, Inoue K, Ishiguro Y, Ishikawa T, Ishimoto S, Ishiwatari T, Itahashi K, Iwai M, Iwasaki M, Kato Y, Kawasaki S, Kienle P, Kou H, Ma Y, Marton J, Matsuda Y, Mizoi Y, Morra O, Nagae T, Noumi H, Ohnishi H, Okada S, Outa H, Piscicchia K, Poli Lener M, Romero Vidal A, Sakaguchi A, Sakuma F, Sato M, Scordo A, Sekimoto M, Shi H, Sirghi D, Sirghi F, Suzuki K, Suzuki S, Suzuki T, Tanida K, Tatsuno H, Tokuda M, Tomono D, Toyoda A, Tsukada K, Vazquez Doce O, Widmann E, Weunschek BK, Yamaga T, Yamazaki T, Yim H, Zhang Q, Zmeskal J. Search for the K−ppbound state via the in-flight 3He( K−, n) reaction. EPJ Web of Conferences 2014. [DOI: 10.1051/epjconf/20148102016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Nakata J, Nakano K, Okumura A, Mizutani Y, Kinoshita H, Iwai M, Hasegawa K, Morimoto S, Fujiki F, Tatsumi N, Nakajima H, Nakae Y, Nishida S, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kumanogoh A, Hosen N. In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia 2013; 28:1316-25. [DOI: 10.1038/leu.2013.374] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Revised: 10/26/2013] [Accepted: 12/10/2013] [Indexed: 12/18/2022]
|
26
|
Hu X, Zhang F, Leak R, Zhang W, Iwai M, Stetler R, Dai Y, Zhao A, Gao Y, Chen J. Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke. Curr Mol Med 2013; 13:1465-73. [DOI: 10.2174/15665240113139990075] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2011] [Revised: 02/17/2012] [Accepted: 06/10/2013] [Indexed: 11/22/2022]
|
27
|
van den Broek JS, Hoekstra T, Drechsler C, Brandenburg VM, Dekker FW, Vervloet MG, Albrizio P, Sepe V, Gnecchi M, Cervio E, Mangione F, Fiorini F, Rampino T, Libetta C, Dal Canton A, Di Marco G, Reuter S, Kentrup D, Tiemann K, Fobker M, Engelbertz C, Breithardt G, Reinecke H, Brand E, Pavenstadt H, Brand M, De Mauri A, Conti N, Chiarinotti D, David P, Capurro F, De Leo M, Delanaye P, Krzesinski JM, Warling X, Smelten N, Cavalier E, Hayashi M, Kanno Y, Iwai M, Yoshida T, Abe T. Cardiovascular disease in CKD. Nephrol Dial Transplant 2013. [DOI: 10.1093/ndt/gft141] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Iwai M, Sone H, Kanno H, Moritani T, Horiuchi M. Reciprocal regulation of cholesterol excretion in apolipoprotein E-null mice by angiotensin II type 1 and type 2 receptor deficiency. Life Sci 2013; 92:276-81. [PMID: 23333824 DOI: 10.1016/j.lfs.2012.12.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Revised: 11/30/2012] [Accepted: 12/21/2012] [Indexed: 11/29/2022]
Abstract
AIMS The effects of AT(1) and AT(2) receptor deficiency on the intake and excretion of cholesterol were examined using atherosclerotic apolipoprotein E-null (ApoEKO) mice. MAIN METHODS ApoEKO, AT(1)a/ApoEKO and AT(2)/ApoEKO mice received a high-cholesterol diet (HCD: 1.25% cholesterol) for 10 days before sampling. KEY FINDINGS Plasma total cholesterol level was lower in AT(1)a/ApoEKO mice and higher in AT(2)/ApoEKO mice than in ApoEKO mice with a high cholesterol intake. In these mice, cholesterol content in feces was higher in AT(1)a/ApoEKO mice and lower in AT(2)/ApoEKO mice than in ApoEKO mice. Moreover, cholesterol content in bile tended to be higher in AT(1)a/ApoEKO mice and lower in AT(2)/ApoEKO mice than in ApoEKO mice, while a significant difference was observed only between AT(1)a/ApoEKO and AT(2)/ApoEKO mice. Cholesterol content and expression of HMG-CoA reductase and LDL receptor in liver were not different among the groups. Similar but weaker changes were also observed with a normal standard diet. Treatment with an AT(1) receptor blocker, irbesartan, increased cholesterol content in bile and tended to increase cholesterol excretion into feces in ApoEKO mice with HCD. SIGNIFICANCE These results suggest that AT(1) and AT(2) receptor stimulation was involved in the regulation of cholesterol excretion into bile and feces, and that the regulation acted reciprocally in a cholesterol overload condition with HCD.
Collapse
Affiliation(s)
- Masaru Iwai
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime, Japan
| | | | | | | | | |
Collapse
|
29
|
|
30
|
Sato K, Shinozaki N, Iwai M, Mizuno Y, Shimoyama R, Takahashi N, Niitsu Y. Web-based standard-regimen selection (SRS) and cancer-care registry (CCR) systems of a nationwide network in Japan: An attempt to improve breast cancer treatment. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.27_suppl.76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
76 Background: Tokushukai group has a nation-wide network of 67 affiliated hospitals, and has started an “oncology project” to improve the quality of cancer care using web-based SRS and CCR systems. Methods: Every institution has been introduced the same electric-medical-record (EMR) to share the unified code to order chemotherapy regimens, and patient data could be collected on a database in the central office. 141 recommended regimens for 15 types of solid tumor have been approved in the cancer committee consisting of working-group and program-evaluation members. In breast cancer, 31 recommended regimens (7 for adjuvant and 24 for metastatic settings) were selected from the NCCN guidelines and approved by the committee. Not only recommended but also non-recommended regimens have their own specific codes in EMR, and the patterns of care in the selection of chemotherapy regimen were examined. Results: In 2011, 21 of 67 hospitals utilized these systems. 71.8% of 2,676 patients with cancer including 753 with colorectal, 317 with breast, 273 with gastric, 144 with non-small cell lung, 123 with pancreatic, and 73 patients with esophageal cancer had received 97 types of recommended therapies (11,022 cycles). In terms of breast cancer, 86% of 388 patients had been treated with recommended regimens (1,994 cycles). Among 71 patients received non-recommend therapies, only 6 patients (1.5%) had been treated with three regimens which were not regarded as standard regimens. Conclusions: The introduction of web-based SRS and CCR systems in a large medical group could facilitate standard chemotherapy regimen by an accurate examination of current treatment patterns.
Collapse
Affiliation(s)
- Kazuhiko Sato
- Breast Oncology Center, Tokyo-West Tokushukai Hospital, Tokyo, Japan
| | | | - Masaru Iwai
- Tokyo-West Tokushukai Hospital, Tokyo, Japan
| | - Yoshio Mizuno
- Breast Oncology Center, Tokyo-West Tokushukai Hospital, Tokyo, Japan
| | | | | | | |
Collapse
|
31
|
Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension 2012; 60:137-44. [PMID: 22665126 DOI: 10.1161/hypertensionaha.112.191452] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We explored the roles of angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7), and Mas activation in angiotensin II type 1 receptor blockade-mediated attenuation of vascular remodeling. Vascular injury was induced by polyethylene-cuff placement around the mouse femoral artery. After cuff placement, the mRNA level of both ACE2 and Mas was markedly decreased in wild-type mice, whereas ACE mRNA was not changed. Immunostaining of ACE2 and Mas was observed mainly in the media and was reduced in the injured artery. Administration of angiotensin-(1-7) decreased neointimal formation after cuff placement, whereas administration of [D-Ala(7)] angiotensin-(1-7), a Mas antagonist, increased it. Consistent with these results, we also demonstrated that neointimal formation induced by cuff placement was further increased in ACE2 knockout mice. In angiotensin II type 1a receptor knockout mice, mRNA expression and immunostaining of ACE2 and Mas in the injured artery were greater, with less neointimal formation than in wild-type mice. Increased ACE2 expression in the injured artery was also observed by treatment of wild-type mice with an angiotensin II type 1 receptor blocker, olmesartan. These results suggested that activation of the ACE2-angiotensin-(1-7)-Mas axis is at least partly involved in the beneficial effects of angiotensin II type 1 receptor blockade on vascular remodeling.
Collapse
Affiliation(s)
- Masaru Iwai
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime 791-0295, Japan
| | | | | | | | | | | |
Collapse
|
32
|
Aono J, Suzuki J, Iwai M, Horiuchi M, Nagai T, Nishimura K, Inoue K, Ogimoto A, Okayama H, Higaki J. Deletion of the Angiotensin II Type 1a Receptor Prevents Atherosclerotic Plaque Rupture in Apolipoprotein E
−/−
Mice. Arterioscler Thromb Vasc Biol 2012; 32:1453-9. [DOI: 10.1161/atvbaha.112.249516] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Angiotensin II is involved in the genesis of atherosclerosis. As the role of the angiotensin II type 1a (AT
1a
) receptor in plaque rupture is poorly understood, we assessed the hypothesis that the AT
1a
receptor contributes to atherosclerotic plaque rupture.
Methods and Results—
Atherosclerotic plaque rupture was induced by carotid artery ligation for 4 weeks followed by polyethylene cuff placement around the carotid in apolipoprotein E (ApoE)
−/−
and ApoE
−/−
AT
1a
−/−
mice. The incidence of plaque rupture at 4 days after cuff placement was 72% in ApoE
−/−
mice compared with 24% in ApoE
−/−
AT
1a
−/−
mice (
P
<0.01). Lipid accumulation, macrophage infiltration, expression of inflammatory cytokines, nicotinamide adenine dinucleotide phosphate-oxidase activity, and matrix metalloproteinase-9 activity in atherosclerotic plaque were markedly attenuated in ApoE
−/−
AT
1a
−/−
compared with ApoE
−/−
mice. Oxidized low-density lipoprotein inhibited macrophage migration in ApoE
−/−
macrophages. In contrast, oxidized low-density lipoprotein-induced macrophage trapping was abolished in ApoE
−/−
AT
1a
−/−
macrophages, and this was associated with decreased CD36 expression and focal adhesion kinase activity.
Conclusions—
Conclusion—
These results suggest that blocking the AT
1
receptor may reduce atherosclerotic plaque rupture and that AT
1a
receptor-mediated macrophage trapping, inflammation, oxidative stress, and matrix metalloproteinase activation may play crucial roles in plaque vulnerability.
Collapse
Affiliation(s)
- Jun Aono
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Jun Suzuki
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Masaru Iwai
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Masatsugu Horiuchi
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Takayuki Nagai
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Kazuhisa Nishimura
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Katsuji Inoue
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Akiyoshi Ogimoto
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Hideki Okayama
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| | - Jitsuo Higaki
- From the Department of Integrated Medicine and Informatics (J.A., J.S., T.N., K.N., K.I., A.O., H.O., J.H.) and Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime Japan
| |
Collapse
|
33
|
Kato T, Yamada H, Kawahito H, Irie D, Ikeda K, Okigaki M, Mogi M, Iwai M, Horiuchi M, Matsubara H. Abstract 528: Bone Marrow Angiotensin AT2 Receptor Deficiency Aggravates Atherosclerosis by Eliminating Macrophage Liver X Receptor-Mediated Antiatherogenic Actions. Arterioscler Thromb Vasc Biol 2012. [DOI: 10.1161/atvb.32.suppl_1.a528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
[BACKGROUND]
The angiotensin II (Ang II) type 2 (AT2) receptor is crucially involved in atherogenesis; however, bone marrow (BM) AT2-mediated anti-atherogenic action remains undefined.
[METHOD AND RESULT]
We generated BM chimera apoE-deficient (apoE-/-) mice whose BM cells were repopulated with AT2-deficient (Agtr2-/-) or wild type (Agtr2+/+) cells. Eight weeks after BM transplantation, all mice were fed a western diet for two months. Atherosclerotic lesion area was significantly increased in apoE-/-/BM-Agtr2
-/-
mice compared with apoE-/-/BM-Agtr2+/+ mice (51%, P<0.05), accompanied by the enhanced accumulation of MOMA-2 positive cells (P<0.05). Hemodynamic data and lipid profile did not differ between the two groups. We first examined the expression levels of macrophage liver X receptors (LXRα and β), which have been reported to exert anti-atherogenic actions by reducing pro-inflammatory response and promoting cholesterol efflux and macrophage emigration. The mRNA expression of LXRβ, but not LXRα, was significantly decreased by 21% in Agtr2
-/-
thioglycollate-induced peritoneal macrophages (TGPM) compared with Agtr2+/+ TGPM (P<0.01). Inversely, LXRβ mRNA expression was markedly increased by co-treatment of angiotensin II (100nM) with AT1 receptor blocker, Olmesartan (10μM) (47%, p<0.01). Treatment with LXR agonist (GW3965) significantly attenuated LPS-induced mRNA expressions of TNF-α and IL-1β in Agtr2+/+ TGPM (35%, 46%, respectively, P<0.01), however, anti-inflammatory effect of LXR agonist was markedly reduced in Agtr2
-/-
TGPM (p<0.05). Furthermore, the expression levels of ATP-binding cassette transporter ABCA1 and CCR7, essentially implicated in cholesterol efflux and macrophage emigration, were much lower in Agtr2
-/-
TGPM than Agtr2+/+ TGPM (34%, 53%, p<0.01). Flow cytometric analysis also showed a significantly lower expression of CCR7 in Agtr2
-/-
TGPM (24%, p<0.05).
[CONCLUSION]
Our findings demonstrate that BM-AT2 deficiency aggravates atherosclerosis, at least in part, by eliminating anti-atherogenic properties elicited by macrophage LXR activation, suggesting that AT2-mediated regulation of macrophage LXR activity could be a novel therapeutic target for the prevention of atherosclerosis.
Collapse
Affiliation(s)
- Taku Kato
- Kyoto Prefectural Univ, Kyoto City, Japan
| | | | | | | | | | | | - Masaki Mogi
- Molecular Cardiovascular Biology and Pharmacology, Ehime Univ Graduate Sch of Medicine, Ehime, Japan
| | - Masaru Iwai
- Molecular Cardiovascular Biology and Pharmacology, Ehime Univ Graduate Sch of Medicine, Ehime, Japan
| | - Masatsugu Horiuchi
- Molecular Cardiovascular Biology and Pharmacology, Ehime Univ Graduate Sch of Medicine, Ehime, Japan
| | | |
Collapse
|
34
|
Iwai M, Senba I, Kanno H, Nakaoka H, Inaba S, Horiuchi M. Renin inhibitors inhibited the activity of recombinant human renin but not activity in healthy human plasma. Clin Lab 2012; 58:291-298. [PMID: 22582503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Activity of renin substrate cleavage (renin-like activity) was measured in vitro in plasma samples obtained from healthy human volunteers. METHODS Renin-like activity was determined using FRET (Fluorescence Resonance Energy Transfer) human renin substrate. Recombinant human renin and human plasma showed dose-dependent cleavage activity of FRET human renin substrate. RESULTS Activity of recombinant human renin was completely inhibited by either a peptidergic or a non-peptidergic renin inhibitor. However, renin-like activity in human plasma was not inhibited by these renin inhibitors. In a mixture of recombinant renin and human plasma, renin inhibitors inhibited only that part of the activity caused by recombinant renin, while the activity in plasma still remained. Human plasma did not show cleavage activity of rat FRET renin substrate. Native human prorenin showed cleavage activity of human renin substrate. This activety was also completely inhibited by renin inhibitors. Immunoprecipitation with anti-renin or anti-prorenin antibodies did not reduce the activity in human plasma. Renin-like activity in human plasma was abolished by degeneration of protein when sample was heated to 95 degrees C. Activity of both recombinant renin and human plasma was significantly inhibited by a protease inhibitor cocktail. CONCLUSIONS These results suggest that the activity of renin substrate cleavage in human plasma is not mainly caused by the renin or prorenin molecule, but probably by other proteases.
Collapse
Affiliation(s)
- Masaru Iwai
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | | | | | | | | | | |
Collapse
|
35
|
Uto S, Kawakami K, Umena Y, Iwai M, Ikeuchi M, Shen JR, Kamiya N. Crystallization and structure analysis of a PsbM-deletion mutant of PSII. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311081256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
36
|
Wardat S, Iwai M, Horiuchi M, Dahlöf B, Hallberg A, Unger T, Kintscher U, Steckelings UM, Foryst-Ludwig A. Angiotensin AT2R stimulation improves glucose tolerance and insulin sensitivity in obese mice. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling. Am J Hypertens 2011; 24:550-6. [PMID: 21293390 DOI: 10.1038/ajh.2011.6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The present study examined the inhibitory action of temporary treatment with an angiotensin type 1 (AT(1)) receptor blocker (ARB) on vascular remodeling using hypertensive mice with overexpression of the human renin (hRN) and angiotensinogen (hANG) genes. METHODS hRN/hANG transgenic mice (hRN/hANG-Tg) were treated with an ARB, valsartan, from 4 weeks of age. In some mice, valsartan treatment was stopped at 8 weeks of age (temporary treatment). Inflammatory vascular injury was induced by polyethylene-cuff placement around the femoral artery at the age of 10 weeks. RESULTS Compared with wild-type (WT) mice, hRN/hANG-Tg showed higher blood pressure (BP) and enhancement of oxidative stress and medial thickening even before cuff placement. Inflammatory vascular remodeling and oxidative stress after cuff placement were further enhanced in hRN/hANG-Tg. Temporary treatment with valsartan continuously lowered BP even after cessation of administration, and inhibited these changes. In contrast, administration of hydralazine lowered BP to a similar level to that with valsartan, but did not inhibit medial thickening and inflammatory vascular remodeling. In contrast to the valsartan treatment, BP immediately increased to the untreated level after cessation of hydralazine. CONCLUSIONS These results indicate that temporary ARB treatment leads to prolonged effect of BP lowering and prevents vascular remodeling in hypertensive mice induced by activation of the human renin-angiotensin system. The inhibitory action of valsartan is not due to the BP lowering but is at least in part due to a decrease in oxidative stress and inflammation.
Collapse
|
38
|
Okumura M, Iwai M, Nakaoka H, Sone H, Kanno H, Senba I, Ito M, Horiuchi M. Possible involvement of AT2 receptor dysfunction in age-related gender difference in vascular remodeling. ACTA ACUST UNITED AC 2011; 5:76-84. [DOI: 10.1016/j.jash.2011.01.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2010] [Revised: 01/25/2011] [Accepted: 01/25/2011] [Indexed: 11/26/2022]
|
39
|
Iwai M, Kanno H, Senba I, Nakaoka H, Moritani T, Horiuchi M. Irbesartan increased PPARγ activity in vivo in white adipose tissue of atherosclerotic mice and improved adipose tissue dysfunction. Biochem Biophys Res Commun 2011; 406:123-6. [DOI: 10.1016/j.bbrc.2011.02.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2011] [Accepted: 02/01/2011] [Indexed: 12/16/2022]
|
40
|
Iwai M, Kanno H, Inaba S, Senba I, Sone H, Nakaoka H, Horiuchi M. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. Am J Hypertens 2011; 24:169-74. [PMID: 20847723 DOI: 10.1038/ajh.2010.198] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND To explore the metabolic actions of nifedipine on diabetes, we examined glucose intolerance and white adipose tissue changes in type 2 diabetic KK-A(y) mice. METHODS Male KK-A(y) mice were treated with nifedipine (1.5 mg/kg/day in lab chow) for 5 weeks, which did not affect blood pressure or feeding of KK-A(y) mice. RESULTS After treatment with nifedipine, body weight tended to decrease and the weight of white adipose tissue was reduced. Without food restriction, nifedipine decreased plasma insulin level, while plasma glucose level tended to decrease. In oral glucose tolerance test, nifedipine suppressed the increase in glucose level after a glucose load without affecting plasma insulin concentration. Nifedipine also improved the result of insulin tolerance test. In white adipose tissue, nifedipine increased adipocyte number and the expression of peroxisome proliferator-activated receptor-γ (PPARγ) and adipocyte fatty acid-binding protein related to adipocyte differentiation. In addition, expression of adiponectin, insulin receptor, insulin receptor substrate-1, and glucose transporter type-4 was also increased by nifedipine. Nifedipine also increased the expression of NO synthase in white adipose tissue. Nifedipine did not affect expression of angiotensin II type 1 (AT₁) and type 2 (AT₂) receptors in white adipose tissue. Such changes in white adipose tissue were apparent in retroperitoneal adipose tissue. Nifedipine did not change the expression of angiotensin receptors, renin receptor, and angiotensinogen in white adipose tissue. Moreover, nifedipine attenuated nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and increased superoxide dismutase (SOD) activity in white adipose tissue. CONCLUSION These results suggest that nifedipine can enhance insulin sensitivity and reduce white adipose tissue, possibly related to stimulation of adipocyte differentiation.
Collapse
|
41
|
Iwai M, Horiuchi M. [Renin inhibitor]. Nihon Rinsho 2010; 68 Suppl 9:166-171. [PMID: 21661153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Affiliation(s)
- Masaru Iwai
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine
| | | |
Collapse
|
42
|
Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. O4‐01‐04: Beneficial effects of angiotensin II receptor blockers on metabolic disorder‐induced cognitive impairment. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Jun Iwanami
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | - Masaki Mogi
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | - Kana Tsukuda
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | - Li-Juan Min
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | - Akiko Sakata
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | - Fei Jing
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | - Masaru Iwai
- Ehime University Graduate School of MedicineTohon Ehime Japan
| | | |
Collapse
|
43
|
Tsukuda K, Mogi M, Iwanami J, Li JM, Min LJ, Sakata A, Jing F, Iwai M. P3‐271: Telmisartan, an angiotensin II receptor blocker, ameliorates cognitive impairment induced by amyloid beta injection partly due to partial agonistic activation of PPAR‐gamma. Alzheimers Dement 2010. [DOI: 10.1016/j.jalz.2010.05.1771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Kana Tsukuda
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Masaki Mogi
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Jun Iwanami
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Jian-Mei Li
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Li-Juan Min
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Akiko Sakata
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Fei Jing
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| | - Masaru Iwai
- Masatsugu Horiuchi, Ehime University Graduate School of Medicine TohonEhime Japan
| |
Collapse
|
44
|
Sakata A, Mogi M, Iwanami J, Tsukuda K, Min LJ, Jing F, Iwai M, Ito M, Horiuchi M. Female exhibited severe cognitive impairment in type 2 diabetes mellitus mice. Life Sci 2010; 86:638-45. [DOI: 10.1016/j.lfs.2010.03.003] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2009] [Revised: 12/18/2009] [Accepted: 02/02/2010] [Indexed: 10/19/2022]
|
45
|
Yokoi H, Yamada H, Tsubakimoto Y, Takata H, Kawahito H, Kishida S, Kato T, Matsui A, Hirai H, Ashihara E, Maekawa T, Iwai M, Horiuchi M, Ikeda K, Takahashi T, Okigaki M, Matsubara H. Bone Marrow AT
1
Augments Neointima Formation by Promoting Mobilization of Smooth Muscle Progenitors via Platelet-Derived SDF-1α. Arterioscler Thromb Vasc Biol 2010; 30:60-7. [DOI: 10.1161/atvbaha.109.192161] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objectives—
Bone marrow (BM)-derived endothelial progenitor cells (EPCs) and vascular smooth muscle progenitor cells (VPCs) contribute to neointima formation, whereas the angiotensin II (Ang II) type 1 receptor (AT
1
)-mediated action on BM-derived progenitors remains undefined.
Methods and Results—
A wire-induced vascular injury was performed in the femoral artery of BM-chimeric mice whose BM was repopulated with AT
1
-deficient (BM-Agtr1
−/−
) or wild-type (BM-Agtr1
+/+
) cells. Neointima formation was profoundly reduced by 38% in BM-Agtr1
−/−
mice. Although the number of circulating EPCs (Sca-1
+
Flk-1
+
) and extent of reendothelialization did not differ between the 2 groups, the numbers of both circulating VPCs (c-Kit
−
Sca-1
+
Lin
−
) and tissue VPCs (Sca-1
+
CD31
−
) incorporated into neointima were markedly decreased in BM-Agtr1
−/−
mice. The accumulation of aggregated platelets and their content of stromal cell–derived factor-1α (SDF-1α) were significantly reduced in BM-Agtr1
−/−
mice, accompanied by a decrease in the serum level of SDF-1α. Thrombin-induced platelets aggregation was dose-dependently inhibited (45% at 0.1 IU/mL,
P
<0.05) in Agtr1
−/−
platelets compared with Agtr1
+/+
platelets, accompanied by the reduced expression and release of SDF-1α.
Conclusions—
The BM-AT
1
receptor promotes neointima formation by regulating the mobilization and homing of BM-derived VPCs in a platelet-derived SDF-1α–dependent manner without affecting EPC-mediated reendothelialization.
Collapse
Affiliation(s)
- Hirokazu Yokoi
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Hiroyuki Yamada
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Yoshinori Tsubakimoto
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Hiroki Takata
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Hiroyuki Kawahito
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Sou Kishida
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Taku Kato
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Akihiro Matsui
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Hideyo Hirai
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Eishi Ashihara
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Taira Maekawa
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Masaru Iwai
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Masatsugu Horiuchi
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Kouji Ikeda
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Tomosaburo Takahashi
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Mitsuhiko Okigaki
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| | - Hiroaki Matsubara
- From the Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Japan (H. Yokoi, H. Yamada, Y.T., H.T., H.K., S.K., T.K., A.M., K.I., T.T., M.O., H.M.); the Department of Transfusion Medicine and Cell Therapy (H.H., E.A., T.M.), Kyoto University Hospital, Japan; and the Department of Molecular Cardiovascular Biology and Pharmacology (M.I., M.H.), Ehime University Graduate School of Medicine, Japan
| |
Collapse
|
46
|
Ajimura S, Beer G, Bhang H, Bragadireanu M, Buehler P, Busso L, Cargnelli M, Choi S, Curceanu C, Enomoto S, Faso D, Fujioka H, Fujiwara Y, Fukuda T, Fukuda Y, Guaraldo C, Hashimoto T, Hayano R, Hiraiwa T, Iio M, Iliescu M, Inoue K, Ishikawa T, Ishimoto S, Ishiwatari T, Itahashi K, Iwai M, Iwasaki M, Kienle P, Kou H, Marton J, Matsuda Y, Mizoi Y, Morra O, Nagae T, Noumi H, Ohnishi H, Okada S, Outa H, Pietreanu D, Sada Y, Sakaguchi A, Sakuma F, Sato M, Sekimoto M, Sirghi D, Sirghi F, Suzuki K, Suzuki S, Suzuki T, Tatsuno H, Tokuda M, Tomono D, Toyoda A, Tsukada K, Widmann E, Yamazaki T, Yim H, Zmeskal J. A search for deeply-bound kaonic nuclear states at J-PARC. EPJ Web of Conferences 2010. [DOI: 10.1051/epjconf/20100307015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Min LJ, Mogi M, Tamura K, Iwanami J, Sakata A, Fujita T, Tsukuda K, Jing F, Iwai M, Horiuchi M. Angiotensin II type 1 receptor-associated protein prevents vascular smooth muscle cell senescence via inactivation of calcineurin/nuclear factor of activated T cells pathway. J Mol Cell Cardiol 2009; 47:798-809. [DOI: 10.1016/j.yjmcc.2009.09.006] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2009] [Revised: 08/28/2009] [Accepted: 09/09/2009] [Indexed: 11/29/2022]
|
48
|
Abstract
Recent clinical studies indicate that blockade of the renin-angiotensin system is important to prevent stroke, and accumulating results of basic research also indicate the possible involvement of the central renin-angiotensin system in ischaemic brain damage and cognition. When the angiotensin II type 1 receptor is blocked by an angiotensin type 1 receptor blocker, unbound angiotensin II acts preferentially on the angiotensin II type 2 (AT(2)) receptor. These results suggest the pathophysiological importance of the AT(2) receptor in the clinical use of angiotensin type 1 receptor blockers, which are widely used in patients with hypertension with the expectation of a decrease in the onset of cardiovascular and cerebrovascular disease. We review here the possible roles of AT(2) receptor activation in the brain, focusing on ischaemic stroke, cognitive function and neurogenesis, and potential effects of specific AT(2) receptor agonists.
Collapse
Affiliation(s)
- Masatsugu Horiuchi
- Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Shitsukawa, Tohon, Ehime 791-0295, Japan.
| | | | | |
Collapse
|
49
|
Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive Deficit in Amyloid-β–Injected Mice Was Improved by Pretreatment With a Low Dose of Telmisartan Partly Because of Peroxisome Proliferator-Activated Receptor-γ Activation. Hypertension 2009; 54:782-7. [DOI: 10.1161/hypertensionaha.109.136879] [Citation(s) in RCA: 150] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The pathological hallmark of Alzheimer disease is deposition of amyloid-β protein (Aβ) in the brain. Telmisartan is a unique angiotensin II receptor blocker with peroxisome proliferator-activated receptor-γ (PPAR-γ)–stimulating activity. Activation of PPAR-γ is expected to prevent inflammation and Aβ accumulation in the brain. We investigated the possible preventive effect of telmisartan on cognitive decline in an Alzheimer disease mouse model via PPAR-γ activation. Here, male ddY mice underwent ICV injection of Aβ 1-40. Cognitive function was evaluated by the Morris water maze test. A low dose of telmisartan (0.35 mg/kg per day) was administered in drinking water with or without GW9662, a PPAR-γ antagonist. Cerebral blood flow was evaluated by laser speckle flowmetry. Inflammatory cytokine levels were measured by quantitative RT-PCR. Aβ 1-40 ICV injection significantly impaired cognitive function. Pretreatment with telmisartan improved this cognitive decline to a similar level to that in control mice. Cotreatment with GW9662, a PPAR-γ antagonist, attenuated this telmisartan-mediated improvement of cognition. Treatment with telmisartan enhanced cerebral blood flow and attenuated the Aβ-induced increase in expression of cytokines, such as tumor necrosis factor-α and inducible NO synthase in the brain. Interestingly, coadministration of GW9662 cancelled these beneficial effects of telmisartan. Aβ 1-40 concentration in the brain was significantly decreased by treatment with telmisartan, whereas administration of GW9662 attenuated the decrease in telmisartan-mediated Aβ 1-40 concentration. Taken together, our findings suggest that even a low dose of telmisartan had a preventive effect on cognitive decline in an Alzheimer disease mouse model, partly because of PPAR-γ activation.
Collapse
Affiliation(s)
- Kana Tsukuda
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Masaki Mogi
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Jun Iwanami
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Li-Juan Min
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Akiko Sakata
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Fei Jing
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Masaru Iwai
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Masatsugu Horiuchi
- From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| |
Collapse
|
50
|
Abstract
PURPOSE To investigate the role of angiotensin II (Ang II) receptor subtypes in subconjunctival injury. METHODS A wound-healing model was developed by subconjunctival blunt dissection in male wild-type, AT1a receptor-deficient (AT1aKO) and AT2 receptor-deficient (AT2KO) mice. Collagen deposition and cell infiltration were evaluated histologically. Expression of collagen, matrix metalloproteinase (MMP), and tissue inhibitor of metalloproteinase-1 (TIMP-1) were determined by real-time PCR. RESULTS Subconjunctival injury increased the infiltration of inflammatory cells, collagen deposition in the subconjunctival space, and the expression of collagen type I and type III, TIMP-1 and MMP2. In AT1aKO mice, collagen deposition, cell infiltration, and expression of collagen and TIMP-1 were inhibited, but MMP2 expression was enhanced. In contrast, in AT2KO mice, the increase in collagen deposition, cell infiltration, and expression of collagen and TIMP-1 were further enhanced. CONCLUSIONS These results indicate that AT1a and AT2 receptor stimulation may in addition to other mechanisms be antagonistically involved in the wound-healing process after subconjunctival injury.
Collapse
MESH Headings
- Animals
- Collagen/genetics
- Collagen/metabolism
- Conjunctiva/injuries
- Conjunctiva/metabolism
- Disease Models, Animal
- Eye Injuries, Penetrating/metabolism
- Male
- Matrix Metalloproteinase 2/genetics
- Matrix Metalloproteinase 2/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- RNA, Messenger/metabolism
- Receptor, Angiotensin, Type 1/physiology
- Receptor, Angiotensin, Type 2/physiology
- Reverse Transcriptase Polymerase Chain Reaction
- Tissue Inhibitor of Metalloproteinase-1/genetics
- Tissue Inhibitor of Metalloproteinase-1/metabolism
- Wound Healing/physiology
Collapse
Affiliation(s)
- Shiro Mizoue
- Department of Ophthalmology, Division of Medical Biochemistry and Cardiovascular Biology, Ehime University School of Medicine, Ehime, Japan
| | | | | | | | | | | | | |
Collapse
|